Related Experiment Video
Updated: Jan 20, 2026
Modeling Breast Cancer in Human Breast Tissue using a Microphysiological System
Published on: April 23, 2021
Can the hormonal receptor status of primary breast cancer be altered by neoadjuvant chemotherapy?
1Department of Surgery, Veterans General Hospital-Taipei, National Yang Ming Medical College, Taiwan.
Abstract:
In order to know whether neoadjuvant chemotherapy would change the hormonal receptor status of primary breast cancer, 10 patients with locally advanced breast cancer treated with neoadjuvant CEF (endoxan, epirubicin, 5-fluorouracil) were studied. Tissue was obtained by incisional biopsy before chemotherapy and by mastectomy after three courses of treatment. All the specimens were subjected to histology study and the tests of estrogen (ER) and progesterone (PgR) receptors. The results revealed that the only hormonal status of one out of 10 tumors was altered. Among the 10 tumors, 2 out of 10 ER and 3 out of 10 PgR were changed after neoadjuvant CEF. From our results together with other findings, it is concluded that neoadjuvant CEF dose not significantly change the hormonal receptor status of primary breast cancer. The hormonal receptor assay is unnecessary before chemotherapy.
Related Concept Videos
08:02Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
10:51Modeling Breast Cancer in Human Breast Tissue using a Microphysiological System
07:45Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
09:29Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
12:31An Ex vivo Model to Study Hormone Action in the Human Breast
15:48Tracking the Mammary Architectural Features and Detecting Breast Cancer with Magnetic Resonance Diffusion Tensor Imaging